BioNTech SE American Depositary Share (BNTX) Stock Price
BNTXStock
$87.71−16.53%52W
Market Cap$22.03B
P/E—
PEG Ratio0.05
Div yield—
Beta1.34
BNTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-20.78%
Price vs S&P 500 (4W)-9.17%
PEG Ratio0.05
VGM Score51.07
BNTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.33 | -$2.49 | -6.80%(-$0.16) | |
| Q1 2026 | -$2.15 | -$2.19 | -1.62%(-$0.03) | |
| Q4 2025 | -$0.28 | -$0.37 | -30.43%(-$0.09) | |
| Q3 2025 | $0.11 | -$0.13 | -220.34%(-$0.25) | |
| Q2 2025 | -$1.58 | -$1.80 | -13.84%(-$0.21) |
BNTX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.04
4.00
4.00
4.00
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About BioNTech SE American Depositary Share
BioNTech is a German biotechnology company developing mRNA-based cancer immunotherapies and vaccines for infectious diseases. Its oncology pipeline includes multiple therapeutic modalities such as mRNA drugs, cell therapies, bispecific antibodies, and antibody-drug conjugates. The company's first commercialized product is Comirnaty, a COVID-19 vaccine developed in partnership with Pfizer.